ISM Therapeutics is a biopharmaceutical company focused on the discovery and development of a new class of therapeutics based on inositol signaling molecules - an approach that can rapidly generate novel medicines for most major diseases. Currently the company, piloted by an experienced leadership team, has discovered a variety of drugs based on this innovative platform and has compounds in development for the treatment of Pulmonary Disorders as well as drugs that can be used as Radioprotective Agents.